Ovarian Cancer

The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.

The overexpression of the gene, BRD4, may be the cause of chemotherapy resistance in patients with high-grade serous ovarian cancer, according to research.

Interim results of a trial displayed promising results for patients with ovarian cancer treated with IMNN-01 with neoadjuvant chemotherapy and a PARP inhibitor.

As Teddi Mellencamp reveals more about her cancer diagnosis and Shannen Doherty receives a standing ovation after her stage 4 cancer diagnosis, here’s what is happening in the oncology space this week.

Recent developments in PARP inhibitor combinations and antibody-drug-conjugates are changing the landscape of ovarian cancer treatment.

Exercise was shown to reduce chemotherapy-induced peripheral neuropathy in ovarian cancer survivors, according to findings from a recent study.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

As Ben Alldis reveals previous cancer diagnosis and Luke Combs brings a Make-a-Wish cancer survivor on stage during a concert venue, this is what’s occurring in the oncology space this week.

Sometimes difficult experiences like cancer can come with blessings in disguise.

Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer.

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery.

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.

A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.

As more personalized treatments become available in the ovarian cancer space, tumor testing, such as next-generation sequencing, may play a bigger role.

The best part of the trip was that I didn’t think about cancer. My husband and I didn’t talk about it for a whole week, and no one knew I had it.

A pharmaceutical company initiated a phase 1b study in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Social media, including Facebook groups, can help connect patients with rare cancers like granulosa cell tumors to researchers, allowing them to learn more about disease management.

Interim findings from a clinical trial showed that adding Lynparza and Imfinzi to an Avastin and chemotherapy regimen tended to improve the time patients lived before their disease got worse.

Twenty-five years ago, I was diagnosed with ovarian cancer, which sparked fears of leaving my loved ones behind.

The temporary tattoos that guided the radiation for my cancer treatment were not beautiful, artistic or cool — they were more than that.

Positive results have emerged from a trial testing PIPAC, a procedure used for appendiceal, ovarian, gastric and colon cancers that works by spraying chemotherapy directly onto tumors.

After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.

I’m coming up on my 10-year cancer anniversary, and it feels bittersweet.

Women with low-grade serous ovarian cancer treated with avutometinib and defactinib experienced positive response rates compared with avutometinib alone.

The trial is evaluating the safety and efficacy of AVB-001 patients with relapsed refractory ovarian cancer.

Women who were taking beta-blockers, a medicine to treat heart conditions like high blood pressure, among others, near the time of surgery for epithelial ovarian cancer may confer a survival benefit years after undergoing a procedure.

One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.